Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Amylyx Pharmaceuticals, Inc. (AMLX) had Stock-Based Compensation of $14.44M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-43.42M |
|
-- |
|
-- |
|
$45.69M |
|
$-45.69M |
|
$2.27M |
|
$-43.42M |
|
$-43.42M |
|
$-43.42M |
|
$-43.42M |
|
$-43.42M |
|
$-43.42M |
|
$-45.69M |
|
$-46.87M |
|
111.20M |
|
111.20M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$256.34M |
|
$0.20M |
|
$8.23M |
|
$264.56M |
|
$21.15M |
|
-- |
|
$4.25M |
|
$25.40M |
|
$239.17M |
|
$239.17M |
|
$239.17M |
|
111.37M |
|
| Cash Flow Statement Financials | |
$-68.31M |
|
$-113.53M |
|
$4.70M |
|
$227.64M |
|
$50.31M |
|
$-177.32M |
|
|
Stock-Based Compensation |
$14.44M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-72.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.16% |
|
-18.16% |
|
-16.41% |
|
-18.16% |
|
$2.15 |
|
$-0.65 |
|
$-0.61 |
|